Palatin Hosting Key Opinion Leader Webinar on Dry Eye Disease

Discuss Ongoing PL9643 Pivotal Phase 3 Clinical Trial Webinar Monday, March 7th at 10:30 AM ET Mar 03, 2022, 07:30 ET CRANBURY, N.J., March 3, 2022 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, today …

Palatin Hosting Key Opinion Leader Webinar on Dry Eye Disease Read More »